CD73 Blockade Reverses Selinexor-Linked Immune Suppression

Institutions: Peking University Third Hospital / Antengene · Compounds: ATG-037 (CD73 Inhibitor) + ATG-010 (Selinexor) · Indication: Multiple Myeloma · Stage: Preclinical · Date: August 27, 2026 Summary A peer-reviewed preclinical study from Peking University collaborators and Antengene identified CD73 upregulation as a potential adaptive…